Bionano Genomics, Inc. BNGO
Nov 3, 2026, 3:15 PM EST
- YTD
- -22.22%
- 1 year
- -30.81%
- Market cap
- 16.77M
- Revenue (ttm)
- 36.58M
- EPS (ttm)
- -3.02
- Shares out
- 101.99M
- Forward P/E
- -0.41
- YTD return
- -22.22%
- 1-year return
- -30.81%
- Volume
- 76.88K
- Avg volume
- 941.89K
- Open
- 1.16
- Previous close
- 1.16
- Day's range
- 1.16 – 1.20
- 52-week range
- 1.00 – 2.23
- Beta
- 2.38
- Price target
- 1.00 (-16.0%)
- Earnings date
- Aug 7, 2024
1D +0.04 (+3.45%)
Key statistics
- Enterprise value
- 30.64M
- PEG ratio
- 0.00
- Price / sales
- 0.56
- Price / book
- 0.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -10.30%
- Free cash flow
- -55.98M
- Total cash
- 18.94M
- Total debt
- 27.57M
- Return on equity
- -138.33%
- Short % of float
- 10.26%
- 50-day average
- 0.2652
- 200-day average
- 0.6133
Analyst view
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.14.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.32 | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | -0.24 | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.00 | -0.60 | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 5, 2024 | Dec 1, 2023 | 0.00 | -0.96 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Ladenburg Thalmann | down | Buy | Neutral |
| May 16, 2024 | BTIG | main | Buy | Buy |
| Mar 7, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Nov 13, 2023 | Maxim Group | down | Buy | Hold |
| Aug 10, 2023 | BTIG | main | Buy | Buy |
About Bionano Genomics, Inc.
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- bionano.com
News
Bionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026
Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
12 Health Care Stocks Moving In Tuesday's After-Market Session
Bionano Genomics Stock Surges Tuesday: What's Going On?
12 Health Care Stocks Moving In Tuesday's Intraday Session Bionano Genomics Highlights Three New Independently Authored, Peer-Reviewed Publications Showing Clinical Utility Of OGM In High-Risk Hematologic Malignancies
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia Bionano Genomics Subsidiary Says MolDX Issues Proposed LCD For Genome-Wide Molecular Methodologies For Detection Of Copy Number Alterations And Structural Variants In Hematologic Neoplasms
Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms
Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping
Your note
Sign in to keep a note on BNGO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAUBEY ALKA PH.D. | Officer | Stock Award(Grant) | Jun 2, 2024 | 48,245 |
| DIXON JONATHAN V | General Counsel | Stock Award(Grant) | Jun 2, 2024 | 18,025 |
| HOLMLIN R ERIK | Chief Executive Officer | Stock Award(Grant) | Jun 2, 2024 | 122,315 |
| KAMA GULSEN | Chief Financial Officer | Stock Award(Grant) | Jun 2, 2024 | 16,000 |
| MAMUSZKA HANNAH | Director | Purchase | Jun 12, 2023 | 65,789 |
| OLDAKOWSKI MARK | Chief Operating Officer | Stock Award(Grant) | Jun 2, 2024 | 64,698 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.15% | 2,192,492 | 443.76K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.87% | 882,854 | 178.69K | Sep 29, 2024 |
| Blackrock Inc. | 0.60% | 614,163 | 124.31K | Sep 29, 2024 |
| GMT Capital Corp | 0.52% | 530,260 | 107.32K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.24% | 249,070 | 50.41K | Sep 29, 2024 |
| Northern Trust Corporation | 0.14% | 147,134 | 29.78K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.34% | 1,364,438 | 276.16K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.50% | 505,292 | 102.27K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 492,060 | 99.59K | Oct 30, 2024 |
| Vanguard Health Care Index Fund | 0.20% | 208,601 | 42.22K | Aug 30, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 166,234 | 33.65K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 116,331 | 23.55K | Oct 30, 2024 |
